Genomic destabilization and its associated mutagenesis increase with senescence-associated phenotype expression

Ken-ichi Yoshioka1 | Yusuke Matsuno1,2

1Laboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Tokyo, Japan
2Department of Applied Chemistry, Tokyo University of Science, Tokyo, Japan

Correspondence
Ken-ichi Yoshioka, Laboratory of Genome Stability Maintenance, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Email: kyoshiok@ncc.go.jp

Abstract
Cancer develops through multiple rounds of clonal evolution of cells with abrogated defense systems. Such clonal evolution is triggered by genomic destabilization with associated mutagenesis. However, what increases the risk of genomic destabilization remains unclear. Genomic instability is usually the result of erroneous repair of DNA double-strand breaks (DSB); paradoxically, however, most cancers develop with genomic instability but lack mutations in DNA repair systems. In this manuscript, we review current knowledge regarding a cellular state that increases the risk of genomic destabilization, in which cells exhibit phenotypes often observed during senescence. In addition, we explore the pathways that lead to genomic destabilization and its associated mutagenesis, which ultimately result in cancer.

KEYWORDS
cell cycle, DNA replication, genetic instability, genomic instability

1 | INTRODUCTION

Most cancers develop genomic instability, which can be categorized as either chromosomal instability (CIN) or microsatellite instability (MSI).1 CIN encompasses a wide variety of chromosomal abnormalities, including chromosome-number alterations (ie, aneuploidy) and chromosomal rearrangements,2,3 whereas MSI is defined as changes in the lengths of microsatellite fragments containing short repetitive sequences.4 Mismatch repair (MMR) status is a major determinant of whether CIN or MSI is induced; MSI is more likely to develop in cells with MMR deficiency.5 Both CIN and MSI are induced through erroneous repair of DNA double-strand breaks (DSB) arising due to replication stress.6

Cancer develops as a consequence of mutations in cancer-driver genes. However, recent studies have illustrated that mutations, including those in cancer-driver genes, accumulate in association with age, even in pathologically normal organs.7,8 This indicates that cancer development is not directly triggered by those mutations, raising the question of what the actual trigger might be. Recent studies have suggested that one trigger is genomic destabilization. Indeed, cancer development is tightly associated with accumulation of genomic abnormalities, which are rarely observed in normal organs even at advanced ages but are widely observed after tumorigenic progression.9,10 In addition, a recent in vitro study revealed that genomic destabilization is associated with mutagenesis and acts as a trigger for clonal evolution of cells with defects in defense systems such as the ARF/p53 pathway.6

In this manuscript, we review the current knowledge about the cellular backgrounds and mechanisms that increase the risk of genomic destabilization (ie, the genomic instability induction associated with CIN and MSI) and other pathways that induce genomic destabilization-associated mutagenesis.
2 | RISK OF GENOMIC DESTABILIZATION AND THE ASSOCIATED CELLULAR STATE

2.1 | Genomic instability and cancer risk

Genomic instability caused by erroneous repair of DSB is associated with cancer development. This phenomenon is clearly illustrated in cells harboring mutations in DNA repair systems. For example, in cells with mutations in the homologous recombination (HR) factors BRCA1 or BRCA2, genomic destabilization is strongly induced, predisposing the cells toward carcinogenesis.\(^\text{11,12}\) Paradoxically, however, most cancers do not harbor any background mutations in DNA repair systems, despite the association between cancer development and genomic instability.\(^\text{13,14}\) This poses the question of what increases the risk of genomic destabilization in normal cells.

2.2 | DNA double-strand breaks accumulate when normal cells exhibit senescence-associated phenotypes

Recent reports have revealed that the DSB repair-defective backgrounds that jeopardize genomic stability are more likely to appear when cells show senescence-associated phenotypes. Cellular senescence, defined as irreversible cell-cycle arrest, is generally induced in association with a series of phenotypes, including persistent DSB accumulation, increased expression of p16\(^\text{Ink4A}\) and the senescence-associated secretory phenotype, and increased activity of senescence-associated β-Gal.\(^\text{15,16}\) In fact, normal cells can accumulate persistent DSB that induce senescence in vitro and aging in vivo.\(^\text{15}\) Although repair factors localize to these DSB, they tend to persist there without completing repair, suggesting repair deficiency.\(^\text{17,18}\) Indeed, those cells are specifically defective in the repair of replication stress-associated DSB, which can cause genomic destabilization.\(^\text{15}\) In addition, cells that accumulate DSB are likely predisposed to genomic destabilization.\(^\text{20,21}\)

Normal cells generally undergo growth arrest after serial proliferation (Figure 1A). The growth-arrested cells can be divided into those that are in a quiescent state (Figure 1B) and those that are in a state characterized by senescence-related phenotypes and DSB. Cells in the former state arrest cell-cycle progression without DSB, as has been widely observed in the cells of healthy organs preserving homeostasis, such as the liver. By contrast, cells in the latter state are often observed in aging organs. These latter cells might not all be in a uniform state, because DSB accumulate as senescence progresses. Therefore, some cells could be in a pre-senescence state (Figure 1C) and others in a canonical senescent state (Figure 1D). Genomic destabilization likely occurs when cells accumulate DSB and are still progressing the cell cycle.\(^\text{6}\) Escaping from senescence, clonal evolution of cells with abrogated defense systems will be induced among a genomic destabilized cell (Figure 1: see cells developing to the state shown in Figure 1E).

The risk of cancer generally increases with age and especially with genomic instability.\(^\text{22,23}\) The main cause of cancer is probably genomic destabilization. Even in normal cells with functional DNA repair systems, the risk of genomic destabilization increases with senescence-associated phenotype expression. First, senescence-associated phenotypes are generally induced in response to DSB when the risk of genomic destabilization is elevated.\(^\text{9,20}\) Second, these phenotypes are

![Figure 1](image-url)
further induced in response to increased amounts of cytosolic DNA, a consequence of chromosomal mis-segregation caused by genomic destabilization. Given that genomic destabilization can trigger clonal evolution of cells with abrogated defense systems, cells with accumulated DSB and senescence-associated phenotypes could be major contributors to cancer development, which usually occurs in the elderly.

2.3 | Repair-defective cellular background

It remains unclear how senescent cells could become defective in repairing DSB. This phenomenon is at least partly due to a reduction in the H2AX level: H2AX, which mediates the damage response by forming γH2AX (phosphorylated H2AX at S139) foci at sites of damage, is significantly downregulated when the growth rate of normal cells slows. This reduction in H2AX level mediates two separate cellular phenotypes, formation of the quiescent cellular state and induction of a repair-defective state. Cells that express very little H2AX can remain continuously quiescent (Figure 1B), like cells in normal organs under tissue homeostasis. However, such cells are sensitive to exogenous growth stimuli that enforce cell-cycle progression, which results in the accumulation of replication stress-associated DSB and an increased risk of genomic destabilization (Figure 1C). Thus, the H2AX-dimensional state is associated with preservation of homeostasis but is simultaneously associated with a repair-defective background, posing the risk of future genomic destabilization (Figure 1B). This is supported by the phenotypes of H2AX-knockout (KO) cells, which exhibit elevated genomic instability; however, H2AX-KO mice are not predisposed to cancer.

Although changes in the levels of H2AX and γH2AX are closely associated with the risk of genomic destabilization, these changes do not explain all of the genomic instability phenotypes observed in cancer cells. For example, cancer cells can recover H2AX expression, but often continue to exhibit higher rates of genomic changes, implying the involvement of another mechanism that further increases the risk of genomic destabilization.

2.4 | Role of ARF/p53 in the formation of the quiescent state

As illustrated in an in vitro model, formation of the H2AX-dimensional quiescent state is regulated by both ARF and p53 (Figure 1B). Therefore, this state can only be induced in normal cells, and not in cancer cells or cells transformed in vitro (Figure 1E). Given that the H2AX-dimensional state is widely observed in normal organs at steady state, quiescence is likely to be associated with preservation of homeostasis and cancer suppression.

Among the targets of p53, those involved in cancer suppression remain unclear. Given that most cancers without mutations in TP53 develop following loss of the CDKN2A gene, which encodes ARF, the cancer-suppressive function of p53 is probably ARF-dependent. However, most p53 targets currently known were discovered in cancer cells harboring mutations in ARF, implying that the role of p53 in cancer suppression might be distinct from the identified p53 targets. In fact, most currently known p53 targets are likely to be involved in acute damage responses but are dispensable for the primary cancer-suppression effect. Importantly, the ARF-dependent cancer-suppression role by p53 may involve the H2AX-dimensional quiescent state induction, because this state can only arise when both ARF and p53 are correctly regulated (Figure 1B). However, it remains unclear how the ARF/p53 pathway mediates H2AX downregulation.

3 | GENOMIC DESTABILIZATION TRIGGERED BY REPLICATION STRESS

3.1 | Replication stress-triggered chromosomal instability induction

Mismatch repair (MMR)-proficient cells usually become defective in the repair of replication stress-associated DSB and develop senescent-associated phenotypes when the risk of CIN is elevated. Such CIN-type genomic instability is induced through erroneous repair of those DSB, which are primarily targeted by factors involved in HR. A wide variety of genomic alterations arise in the resultant cells, including ploidy abnormalities, chromosome rearrangements and losses, gene amplifications and deletions, loss of heterozygosity (LOH), and cytosolic DNA (ie, micronuclei). One outstanding question is how these multiple types of genome-wide alterations are induced. The answer probably has to do with the repair-pathway switch (Figure 2). In fact, although replication stress-associated DSB are the primary target of HR, most genomic rearrangements are joined through the error-prone non–homologous end joining (NHEJ) pathway, suggesting a switch from HR to NHEJ (Figure 2A). This could be the result of cell-cycle carryover of DSB, as seen during tetraploidization. Replication stress-associated DSB arise in cells displaying senescence-associated phenotypes, and are, therefore, often carried over into the M phase. Such carryover can result in tetraploidization because mitotic DSB cause chromosomal mis-segregation, leading to failure of cytokinesis. Importantly, this process could also cause the HR–NHEJ switch, because HR does not operate during G1 phase when DSB are usually repaired by NHEJ. After the collapse of HR intermediates at entry into G1 phase, the DSB end must remain free until a partner DSB end is paired by factors involved in NHEJ. This provides the necessary time window for the generation of genome-wide structural variants such as chromosomal translocations and deletions. Chromosomal translocations associated with DSB carryover have been demonstrated in vitro.
Micronuclei are induced in association with mitotic DSB-mediated chromosomal mis-segregation, resulting in split chromosomal fragments.\textsuperscript{49} Besides tetraploidization, aneuploidy is also widely induced during this process through imbalanced chromosomal segregation and loss of DNA due to micronuclei formation.\textsuperscript{49,50} In addition, because HR does not operate effectively during CIN induction, LOH could also be induced through aberrant HR between allelic chromosomal loci.

3.2 Replication stress-triggered microsatellite instability induction

Microsatellite instability (ie, insertion/deletion errors specifically induced at repetitive loci) is widely observed in MMR-deficient cancer cells.\textsuperscript{5} It was once thought that MSI was induced by replication errors under MMR deficiency.\textsuperscript{51-53} However, recent studies suggest otherwise. In fact, MSI is triggered by replication stress-associated DSB, as an alternative to CIN (Figure 2B).\textsuperscript{6,54} Replication stress-associated DSB in MMR-proficient cells persist continuously throughout S and M phases (Figure 2A), whereas DSB in MMR-deficient cells are primarily recognized by HR factors, but are effectively repaired by MMEJ concomitant with induction of MSI\textsuperscript{6} (Figure 2B). Microsatellite loci (ie, short repetitive sequence patches) are naturally advantageous for microhomology annealing and associated end joining; however, multiple annealing positions could be used, including those with small insertions or deletions, resulting in MSI induction.\textsuperscript{55-57} Because this results in DSB elimination, MSI induction is associated with suppression of CIN.\textsuperscript{6}

Although it remains unclear how the HR–MMEJ switch is specifically induced in an MMR-deficient background, it is probably associated with complex formation.\textsuperscript{58} In fact, MMR factors form large complexes with many repair factors, illustrated by
the BRCA1-associated genome surveillance complex (BASC).\textsuperscript{59} Importantly, clonal evolution is induced in conjunction with MSI and the associated mutagenesis\textsuperscript{5}; MSI induction is accompanied by a very high rate of mutations, even compared to the mutation level induced during canonical replication under MMR deficiency.

4 | GENOMIC DESTABILIZATION AND ASSOCIATED MUTAGENESIS

4.1 | Genomic destabilization-associated mutagenesis

Genomic destabilization is associated with an increased risk of mutagenesis, which results in the clonal evolution of cells with abrogated defense systems.\textsuperscript{6} In fact, many base-substitution mutations in cancer cells are likely to be induced in association with genomic destabilization. A typical example is kataegis; that is, localized hypermutation occurring in a small genomic region that is specifically induced in close proximity to genomic rearrangements.\textsuperscript{60,61} Further supporting this argument, mutations in cancer cells are more likely to accumulate in heterochromatin regions, where chromosomal translocations occur at high frequencies.\textsuperscript{62-64} Furthermore, a recent in vitro model study revealed that the mutation rate in the growing cellular state is limited even in MMR-deficient cells that cannot repair replication errors. By contrast, the mutation rate is highly elevated during genomic destabilization.\textsuperscript{6}

A longstanding question is how mutations that induce clonal evolution are caused. Genomic destabilization-associated mutagenesis is probably the major cause of the resultant clonal evolution. In fact, clonal evolution of cells with mutations in the ARF/p53 module is triggered by genomic destabilization, at least in an in vitro model.\textsuperscript{6}

4.2 | Genomic destabilization-associated induction of cancer-driver mutations

Besides base-substitution mutations, many mutation types can be induced in association with genomic destabilization. This includes chromosomal deletions and translocations, which are inducible by genomic destabilization but not polymerase errors (Figure 3A, B).\textsuperscript{35,36} For example, the cancer suppressor Cdkn2a is often inactivated by deletions.\textsuperscript{40,65-67} In addition, some types of cancer drivers are generated by gene fusions caused by chromosomal translocations.\textsuperscript{68,69}

Loss of heterozygosity also occurs during genomic destabilization and leads to dysfunction of cancer-suppressor genes (Figure 3C).\textsuperscript{38-40} The probability of mutations in both alleles of a gene due to random replication errors or erroneous repair is extremely low. By contrast, LOH could increase the probability of biallelic mutation during genomic destabilization. After one allele is mutated, the second mutation can be induced in a “copying and pasting” manner by erroneous HR between the allelic loci. In this scenario, the probability of mutation propagation is as high as 50%.\textsuperscript{38,70} Indeed, LOH is widely observed in cancer cells and results in the dysfunction of cancer-suppressor genes.\textsuperscript{71}

The rate of base substitutions is also elevated during genomic destabilization (Figure 3D). Replication stress-associated DSB are primarily targeted by HR, in which high-fidelity replicative polymerases do not operate; instead, low-fidelity translesion synthesis (TLS) polymerases with no proofreading activity are induced.\textsuperscript{6,72,73} Indeed, the mutation rate is highly elevated during genomic destabilization.\textsuperscript{6} The induction of hypermutation during DSB repair is similar to somatic hypermutation of immunoglobulin loci, in which mutations other than those caused by deamination are induced by errors of the low-fidelity TLS Polζ during class-switch recombination.\textsuperscript{74,75} Therefore, the rate of base-substitution mutations is also highly elevated when cells are subjected to genomic rearrangements.
4.3 Differences in the spectrum of ARF and p53 mutations between chromosomal instability and microsatellite instability induction backgrounds

It is well established that ARF/p53 mutations are generally a prerequisite for cancer development. Intriguingly, while p53 mutations and deletions are often seen in CIN-associated cancer, they are uncommon in MSI-associated cancer, in which ARF is usually dysfunctional. This suggests that ARF and p53 mutation spectrum may differ between CIN and MSI cell backgrounds. However, the mechanism to cause the different mutation spectrum is still an open question.

5 CANCER RISK

Another important question is whether mutations that promote cancer development are avoidable. It was once thought that most cancers are unavoidable because most mutations in cancer-driver genes are caused by random replication errors in cancer-driver genes (Figure 4A). The standard view was that cancer mutations can be categorized into three types (ie, hereditary, replicative, and environmental). The environmental mutations are avoidable but the others, including mutations randomly induced during replication, are not. Accordingly, secondary prevention is a major priority in efforts to prevent cancer-associated death.

Based on recent findings, however, the above hypothesis is probably untrue. Replicative mutations can be separated into two types: mutations randomly induced as replication errors during active growth (Figure 4A) and genomic destabilization-associated mutations induced by replication stress in cells expressing senescent cellular phenotypes (Figure 4B). The latter is the major type and is closely correlated with the resultant clonal evolution (Figure 4B). Importantly, unlike the former, the latter is theoretically avoidable through maintenance of genome stability. In fact, a recent study revealed that genome stability can be maintained by consumption of certain types of polyphenols that exert a cancer-suppressive effect; however, the mechanism underlying these compounds’ effects on maintenance of genome stability remains unclear. Given that most cancers develop with genomic instability, a cancer-prevention strategy involving maintenance of genome stability might be applicable to many cancers, suggesting a future direction for cancer-prevention research.

DISCLOSURE

The authors have no conflicts of interest to declare.

ORCID

Yusuke Matsuno  https://orcid.org/0000-0001-7611-4811

REFERENCES

1. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-627.
21. Van Riggelen J, Felsher DW. Myc and a Cdk2 senescence switch. *Nature*. 2004;432:338-341.

23. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime incidence of cancer in England and Wales. *Br J Cancer*. 2000;82:776-781.

25. Atsumi Y, Minakawa Y, Ono M, et al. ATM and SIRT6/SNF2H mutations mediate transient H2AX stabilization when DSBs form by blocking HUWE1 to allow efficient γH2AX foci formation. *Cell Rep*. 2015;13:2728-2740.

26. Atsumi Y, Fujimori H, Fukuda H, et al. Onset of quiescence following p53 mediated down-regulation of H2AX in normal cells. *PLoS One*. 2011;6:e23432.

27. Atsumi Y, Inase A, Osawa T, et al. The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs. *J Biol Chem*. 2013;288:13269-13277.

28. Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. *Science*. 2002;296:922-927.

29. Osawa T, Atsumi Y, Sugihara E, et al. Arf and p53 act as guardians of a quiescent cellular state by protecting against immortalization of cells with stable genomes. *Biochem Biophys Res Commun*. 2013;432:34-39.

30. Pinyol M, Hernández L, Martínez A, et al. INK4a/ARF locus alterations in human non-Hodgkin’s lymphomas mainly occur in tumors with wild-type p53 gene. *Am J Pathol*. 2000;156:1987-1996.

31. Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and INK4a-/ARF-deletion appear to be two mutually exclusive events in human glioblastoma. *Oncogene*. 2000;19:3816-3822.

32. Brugarolas J, Chandrasekaran C, Gordon JJ, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature*. 1995;377:552-557.

33. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell*. 2002;109:335-346.

34. Knights CD, Catania J, Di Giovanni S, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. *J Cell Biol*. 2006;173:533-544.

35. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. 2010;463:899-905.

36. Chan YW, Fugger K, West SC. Unresolved recombination intermediates lead to ultra-fine anaphase bridges, chromosome breaks and aberrations. *Nat Cell Biol*. 2018;20:92-103.

37. Geil JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining "chromosomal instability". *Trends Genet*. 2008;24:64-69.

38. Moynahan ME, Jasin M. Loss of heterozygosity induced by a catastrophic nucleosome displacement in mitosis. *Nature Genet*. 1999;24:511-518.

39. Thiagalingam S, Laken S, Willson JKV, et al. Mechanisms underly ing losses of heterozygosity in human colorectal cancers. *Proc Natl Acad Sci U S A*. 1997;94:8988-8993.

40. Thiagalingam S, Laken S, Willson JKV, et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers. *Proc Natl Acad Sci U S A*. 1998:2698-2702.

41. Berggren P, Kumar R, Sakano S, et al. Detecting homologous deletions in the CDKN2A/p16(INK4a)/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. *Clin Cancer Res*. 2003;4:441-444.

42. Hatch EM, Fischer AH, Deerinck TJ, Hetzer MW. Catastrophic nuclear envelope collapse in cancer cell micronuclei. *Cell*. 2013;154:47-54.

43. Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal double-strand break repair are reciprocally regulated through the fission yeast cell cycle. *Genes Dev*. 2004;18:2249-2254.
47. Mao Z, Bozella M, Seluanov A, Gorbunova V. DNA repair by non-homologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle. 2008;7:2902-2906.

48. Nakada S, Katsuki Y, Imoto I, et al. Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest. 2006;116:80-89.

49. Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482:53-58.

50. Thompson SL, Compton DA. Chromosome missegregation in human cells arises through specific types of kinetochore-microtubule attachment errors. Proc Natl Acad Sci U S A. 2011;108:17974-17978.

51. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335-346.

52. Hombauer H, Campbell CS, Smith CE, Desai A, Kolodner RD. Visualization of eukaryotic DNA mismatch repair reveals distinct recognition and repair intermediates. Cell. 2011;147:1040-1053.

53. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.

54. Yoshioka K, Matsuno Y, Hyodo M, Fujimori H. Genomic destabilization-associated mutagenesis and clonal evolution of cells with mutations in tumor-suppressor genes. Cancers. 2019;11:1643.

55. Yan CT, Boboila C, Souza SK, et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature. 2007;449:478-482.

56. Crespan E, Czabany T, Maga G, Hübser U. Microhomology-mediated DNA strand annealing and elongation by human DNA polymerases λ and β on normal and repetitive DNA sequences. Nucleic Acids Res. 2012;40:5577-5590.

57. Sharma S, Javadekar SM, Pandey A, Koleldner RD. Homology and enzymatic requirements of microhomology-dependent alternative end joining. Cell Death Dis. 2015;6:e1697.

58. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BasC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000;14:927-939.

59. Fujimori H, Hyodo M, Matsuno Y, et al. Mismatch repair dependence of replication stress-associated DSB recognition and repair. Heliyon. 2019;5:e03057.

60. Nik-Zainal S, Wedge DC, Alexandrov LB, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46:487-491.

61. Nikiil J, Kumar R, Campbell J, et al. Elevated APOBEC3B expression drives a kataegis-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer. 2017;117:113-123.

62. Schuster-Böckler B, Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature. 2012;488:504-507.

63. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-218.

64. Du Q, Bert SA, Armstrong NJ, et al. Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer. Nat Commun. 2019;10:416.

65. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-756.

66. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.

67. Fargnoli MC, Chimenti S, Peris K, et al. CDKN2a/p16INK4a muta-
tions and Lack of p19ARF involvement in familial melanoma kin-
dreds. J Invest Dermatol. 1998;111:1202-1206.

68. Cleary ML. Oncogenic conversion of transcription factors by chro-
mosomal translocations. Cell. 1991;66:619-622.

69. Downing JR, Head DR, Parham DM, et al. Detection of the (11;22) (q24;q12) translocation of Ewing’s sarcoma and peripheral neuroecto-
todermal tumor by reverse transcription polymerase chain reaction. Am J Pathol. 1993;143:1294-1300.

70. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair de-
fects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776-1782.

71. Peng HQ, Bailey D, Bronson D, Goss PE, Hogg D. Loss of hetero-
zygosity of tumor suppressor genes in testis cancer. Cancer Res. 1995;55:2871-2875.

72. Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer. 2011;11:96-110.

73. Goodman MF, Woodgate R. Translesion DNA polymerases. Cold Spring Harb Perspect Biol. 2013;5:a010363.

74. Rada C, Ehrenstein MR, Neuberger MS, Milstein C. Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity. 1998;9:135-141.

75. Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ. DNA polymerase η is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol. 2001;2:537-541.

76. Donehower LA, Soussi T, Korkut A, Weinstein JN, Akbani R, Correspondence DAW. Integrated analysis of TP53 gene and path-
way alterations in the cancer genome atlas. Cell Rep. 2019;28:1370-1384.e5.

77. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JJ. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology. 2003;124:626-633.

78. Tomasetti C, Vogelstein B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347:78-81.

79. Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355:1330-1334.

80. Matsuno Y, Atsumi Y, Auluddin M, et al. Resveratrol and its related polyphenols contribute to the maintenance of genome stability. Sci Rep. 2020;10:5388.

How to cite this article: Yoshioka K-I, Matsuno Y. Genomic destabilization and its associated mutagenesis increase with senescence-associated phenotype expression. Cancer Sci. 2021;112:515–522. https://doi.org/10.1111/cas.14746